- Home
- SNY vs DMAC Comparison
SNY vs DMAC Comparison
Compare SNY & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- DMAC
- Stock Information
- Founded
- SNY 1994
- DMAC 2000
- Country
- SNY France
- DMAC United States
- Employees
- SNY N/A
- DMAC N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SNY Health Care
- DMAC Health Care
- Exchange
- SNY Nasdaq
- DMAC Nasdaq
- Market Cap
- SNY 116.5B
- DMAC 178.0M
- IPO Year
- SNY N/A
- DMAC N/A
- Fundamental
- Price
- SNY $48.61
- DMAC $3.63
- Analyst Decision
- SNY Buy
- DMAC Strong Buy
- Analyst Count
- SNY 2
- DMAC 2
- Target Price
- SNY $62.50
- DMAC $8.00
- AVG Volume (30 Days)
- SNY 2.2M
- DMAC 325.9K
- Earning Date
- SNY 07-31-2025
- DMAC 08-06-2025
- Dividend Yield
- SNY 3.29%
- DMAC N/A
- EPS Growth
- SNY 39.56
- DMAC N/A
- EPS
- SNY 5.45
- DMAC N/A
- Revenue
- SNY $48,817,552,946.00
- DMAC N/A
- Revenue This Year
- SNY $3.39
- DMAC N/A
- Revenue Next Year
- SNY $7.05
- DMAC N/A
- P/E Ratio
- SNY $8.92
- DMAC N/A
- Revenue Growth
- SNY N/A
- DMAC N/A
- 52 Week Low
- SNY $45.80
- DMAC $2.98
- 52 Week High
- SNY $60.12
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- SNY 46.26
- DMAC 44.55
- Support Level
- SNY $47.99
- DMAC $3.48
- Resistance Level
- SNY $49.43
- DMAC $3.88
- Average True Range (ATR)
- SNY 0.58
- DMAC 0.26
- MACD
- SNY 0.18
- DMAC 0.00
- Stochastic Oscillator
- SNY 56.15
- DMAC 30.10
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.